{
  "id": 4049265,
  "title": "NeoGenomics Stock Just Turned Its First Profit, Creating an Optimal Entry Point",
  "url": "https://urgent.news/2026/08/27/neogenomics-stock-just-turned-its-first-profit-creating-an-optimal",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-27T15:45:02.000Z",
  "source": {
    "name": "Yahoo Finance",
    "slug": "yahoo-finance",
    "url": "https://finance.yahoo.com/markets/stocks/articles/neogenomics-stock-just-turned-first-154502935.html"
  },
  "original_language": "en",
  "account": "NeoGenomics (NEO) is a prominent cancer genetics diagnostics lab, boasting a 100% Buy technical opinion from Barchart and overwhelmingly bullish analyst sentiment. Its recent profitability marks a prime opportunity for investors. Specializing in various testing services, NEO caters to pathologists, oncologists, urologists, hospitals, and other reference labs across the United States.\n\nThe company's stock hit a two-year high of $19.15 on August 27, soaring 170.27% in the past 52 weeks. Currently trading at $19.27, NEO has a 50-day moving average of $14.94, with 10 new highs and a 45.62% gain in the last month. Support levels are around $16.82, while projected revenue growth is 10.55% this year and 10.07% next year. Earnings are expected to increase by 31.17% this year and 13.68% the following year.\n\nAnalysts at Barchart have given NEO a 2-year high and a Trend Seeker Buy signal since July 29, resulting in a 26.39% gain. Morningstar considers the stock 13% overvalued, with a fair value of $15.27. TipRanks analysts project a 5.55% gain, with price targets between $16 and $21. With 12% of the float shorted, NEO's trading is highly volatile, and investors are advised to follow diversification and stop loss strategies suitable to their personal risk tolerance.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}